Clinical trial ETOP 12-17 ALERT-lung
A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC (ETOP 12-17 ALERT-lung)
| Cancers | |
|---|---|
| Organ | NSCLC |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | IBCSG |
| EudraCT Identifier | 2017-002063-17 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03445000 |
| Inclusion criteria | At least one prior platinum-based systemic regimen/ RET |
| Last update |